Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus MYHIBBIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus MYHIBBIN.
KERYDIN vs MYHIBBIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Category C
Category C
Antifungal
Antifungal